Transcriptomics-Based Phenotypic Screening Supports Drug Discovery in Human Glioblastoma Cells
We have used three established human glioblastoma (GBM) cell lines—U87MG, A172, and T98G—as cellular systems to examine the plasticity of the drug-induced GBM cell phenotype, focusing on two clinical drugs, the phosphodiesterase PDE10A inhibitor Mardepodect and the multi-kinase inhibitor Regorafenib...
Main Authors: | Vladimir Shapovalov, Liliya Kopanitsa, Lavinia-Lorena Pruteanu, Graham Ladds, David S. Bailey |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/15/3780 |
Similar Items
-
Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study
by: Giuseppe Lombardi, et al.
Published: (2021-09-01) -
Suppression of Proliferation of Human Glioblastoma Cells by Combined Phosphodiesterase and Multidrug Resistance-Associated Protein 1 Inhibition
by: Liliya Kopanitsa, et al.
Published: (2021-09-01) -
METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01) -
Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients
by: Pia S. Zeiner, et al.
Published: (2019-11-01) -
Drug target ranking for glioblastoma multiforme
by: Radhika Saraf, et al.
Published: (2021-04-01)